Organic Sythesis

有机合成核心设施（OSCF）的使命是为 MSKCC社区，并保持一个国家的最先进的设施与专家的专业人员在化学 合成.这个化学核心设施在化学，生物学和医学的界面上运行，并具有 支持医学化学工作的能力，以发展阴性试剂，支持MSKCC研究者。 核心的工作极大地促进了中心的临床前研究。核心合成小说 通过遵循所描述的程序或通过开发新的和 更合适的合成方法。MSKCC致力于新工具的研发 以及用于癌症检测、预防和治疗的治疗剂。提供的专业服务 在过去的一年里，有机合成核心支持了16名研究人员的研究。在过去 赠款期间，核心的工作为来自5个研究领域的研究人员的60篇出版物做出了贡献。 程序.例如，Sawyers实验室利用Core的服务开发了一种新的雄激素， 受体拮抗剂作为前列腺癌的潜在治疗。在相对较短的时间内，内核能够 发明了一种新的化学方法来合成一种安全、可扩展和可重复的拮抗剂。最 重要的是，对交付批次的控制使得在批次生物利用度 评估差别很大。到目前为止，这已经产生了两项授权专利，一个高调的论文， 最重要的是一种具有理想特性的药物，现在被称为ARN-509，很快将进入第三阶段 评估去势抵抗性前列腺癌。

The mission of the Organic Synthesis Core Facility (OSCF) is to provide chemical synthesis services to the MSKCC community, and to maintain a state-of-the art facility with expert professional personnel in chemical synthesis. This Chemistry Core Facility operates at the interface of chemistry, biology and medicine, and has the capability to support medical chemistry efforts to evolve neg agents in support of MSKCC investigators. The work of the Core has greatly facilitated preclinical studies at the Center. The Core synthesizes novel molecules that are not readily available, by either following described procedures or by developing new and more suitable methods of synthesis. MSKCC is committed to the research and development of new tools and therapeutic agents for cancer detection, prevention, and treatment. The specialized services provided by the Organic Synthesis Core have supported the research of 16 investigators in the past year. During the past grant period the work of the Core has contributed to 60 publications of researchers from 5 research programs. For example, the Sawyers laboratory used the Core's services to develop a new androgen receptor antagonist as a potential therapy for prostate cancer. In a relatively short time, the Core was able to invent a new chemical process to synthesize an antagonist that was safe, scalable, and reproducible. Most importantly, controls of delivered batches made it easy to adjust the methodology when batch bioavailability assessments varied significantly. This has so far resulted in two licensed patents, a high profile paper, and most importantly a drug with desirable properties, now known as ARN-509, that will shortly enter Phase III evaluation in castrate resistant prostate cancer.